Iwk Health Centre

VITdALIZE-KIDS is a phase III, multicenter, double-blind RCT designed with CCCTG to assess vitamin D supplementation in PICU patients. The trial will recruit 766 patients from 11 Canadian centers, with randomization stratified by site. The primary outcome is HRQL at 28 ± 7 days post-intervention, measured by PedsQL™. A metabolomics sub-study will analyze blood and urine samples to understand the broader metabolic effects of vitamin D correction. Safety monitoring includes reporting adverse events and following Health Canada guidelines. The trial protocol adheres to SPIRIT guidelines and has received necessary ethical and regulatory approvals.